ClinicalTrials.gg
Sign In

Neurotoxicity Syndromes clinical trials

The registry lists 133 studies for Neurotoxicity Syndromes across more than 10 countries. 17 are recruiting or about to start. 56 of them are mainly about Neurotoxicity Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Tardive Dyskinesia: 215 studies, 29 open.

Get an email when these change. Save the Neurotoxicity Syndromes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
72
Status unknown
17
Recruiting
15
Terminated
13
Active, not recruiting
8
Withdrawn
5

Phase

Phase 3
33
Phase 2
21
Phase 4
8
Phase 1
5
Early Phase 1
3

Where

United States
76
China
12
Canada
10
France
8
Italy
6
Spain
5

Who runs them

Alliance for Clinical Trials in Oncology (12) · Gynecologic Oncology Group (6) · National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4) · Radiation Therapy Oncology Group (3) · Children's Oncology Group (3) · University of South Florida (3) · University Hospital, Montpellier (3)

What is being tested here

Drugs under test in Neurotoxicity Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Tacrolimus103
Duloxetine112
Paclitaxel015
Carboplatin023
Oxaliplatin013
Remifentanil012
Dexmedetomidine012
Dexamethasone002
Calcium Gluconate022
Magnesium Sulfate022

Drug classes tested here Antimitotic agents 7 · Alkylating agents 3 · Antimetabolites 3

Coming up

3phase 3 studies under way
8studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 15 Neurotoxicity Syndromes studies recruiting now, 11 (73%) set no upper age limit and 1 (7%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (13%) take healthy volunteers.

Recruiting studies that take each age, of 15
AgeWomenMen
100 (0%)0 (0%)
1815 (100%)15 (100%)
3015 (100%)15 (100%)
4015 (100%)15 (100%)
5015 (100%)15 (100%)
6515 (100%)15 (100%)
7514 (93%)14 (93%)
8511 (73%)11 (73%)

Across all 133 studies, recruiting or not: 26% stop at 75 or younger and 21% at 65; 23% take children; 11% are for women only and 2% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neurotoxicity Syndromes studies take

Of 20 observational studies under Neurotoxicity Syndromes, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational33 mo18–… · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 133. Browse all 133 → or search them.